PD-1

Open Access
Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival
LUKAS GOERDT, ALEKSANDRA STEFANOVIC, RALPH WIRTZ, UROS KARIC, MAXIMILIAN KOHLER, THOMAS M. DEUTSCH, ANDREAS SCHNEEWEISS, MARC SÜTTERLIN, STEFAN STEFANOVIC, JAN HOFMANN and MARKUS WALLWIENER

In Vivo March 2025, 39 (2) 758-765; DOI: https://doi.org/10.21873/invivo.13880
Open Access
Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer
YUKO KUMAGAI, YURIE FUTOH, HIDEYO MIYATO, HIDEYUKI OHZAWA, HIRONORI YAMAGUCHI, SHIN SAITO, KENTARO KURASHINA, YOSHINORI HOSOYA, ALAN KAWARAI LEFOR, NAOHIRO SATA and JOJI KITAYAMA

In Vivo May 2022, 36 (3) 1126-1135; DOI: https://doi.org/10.21873/invivo.12811
You have access
Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma
MAKI YOSHINO, HIROKI ISHIHARA, YUDAI ISHIYAMA, HIDEKAZU TACHIBANA, DAISUKE TOKI, KAORI YAMASHITA, HIROHITO KOBAYASHI, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, TOSHIO TAKAGI, JUNPEI IIZUKA, HIDEKI ISHIDA, TSUNENORI KONDO and KAZUNARI TANABE

In Vivo September 2021, 35 (5) 2855-2862; DOI: https://doi.org/10.21873/invivo.12573
You have access
PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma
MIN HYE KIM, GYUNG HYUK KO, JEONG HEE LEE, JONG SIL LEE, DONG CHUL KIM, JUNG WOOK YANG, HYO JUNG AN, JI MIN NA and DAE HYUN SONG

In Vivo May 2021, 35 (3) 1549-1553; DOI: https://doi.org/10.21873/invivo.12409
You have access
Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer
YASUYOSHI SATO, NAOKI FUKUDA, YU FUJIWARA, XIAOFEI WANG, TETSUYA URASAKI, AKIHIRO OHMOTO, KENJI NAKANO, MAKIKO ONO, JUNICHI TOMOMATSU, HIROKI MITANI and SHUNJI TAKAHASHI

In Vivo March 2021, 35 (2) 1211-1215; DOI: https://doi.org/10.21873/invivo.12371
You have access
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
TSUKASA HASEGAWA, NORIKO YANAGITANI, HIRONORI NINOMIYA, HIROAKI SAKAMOTO, TAKEHIRO TOZUKA, HIROSHI YOSHIDA, YOSHIAKI AMINO, SHINYA UEMATSU, TAKAHIRO YOSHIZAWA, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, ATSUSHI HORIIKE and MAKOTO NISHIO

In Vivo September 2020, 34 (5) 2997-3003; DOI: https://doi.org/10.21873/invivo.12131
You have access
Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma
HIROKI ISHIHARA, TOSHIO TAKAGI, TSUNENORI KONDO, HIRONORI FUKUDA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, MASAYOSHI OKUMI, HIDEKI ISHIDA and KAZUNARI TANABE

In Vivo May 2020, 34 (3) 1541-1546; DOI: https://doi.org/10.21873/invivo.11943
You have access
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
ATSUTO MOURI, KYOICHI KAIRA, AYAKO SHIONO, YU MIURA and HIROSHI KAGAMU

In Vivo March 2020, 34 (2) 877-880; DOI: https://doi.org/10.21873/invivo.11852
You have access
Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma
HIROYUKI ARIYASU, HIDEFUMI INABA, TAKAYUKI OTA, HIROYUKI YAMAOKA, YASUSHI FURUKAWA, HIROSHI IWAKURA, NAOTAKA DOI, YUKI YAMAMOTO and TAKASHI AKAMIZU

In Vivo March 2018, 32 (2) 345-351;

Main menu

User menu

Search

PD-1